AAC：研究人员开发出能防止艾滋病毒感染的牛奶

2012年10月17日墨尔本研究人员已经开发出一种牛奶能用来保护人类免受艾滋病毒的感染。

全球范围内约30亿人感染了艾滋病毒，目前并没有有效的疫苗。新研究发现牛奶中含有抵御人类免疫缺陷病毒（HIV）的抗体。

墨尔本大学博士Marit Kramski和他的同事发现，使用奶牛产生抑制HIV-抗体比现有的疫苗生产方法更便宜。他们曾与澳大利亚生物技术公司Immuron有限公司开发此类牛奶。科学家们给孕牛接种艾滋病毒蛋白疫苗，奶牛第一次分娩后产出的牛奶中含有抵御人类免疫缺陷病毒（HIV）的抗体。

Marit表示：现在我们能收获含有能作用于艾滋病毒表面蛋白的特异性抗体的牛奶。 我们已经测试了这些抗体，发现这些抗体能结合艾滋病毒，抑制病毒感染和进入人体细胞。

与艾滋病相关的拓展阅读：

• J. Virol.：我国艾滋病感染粘膜疫苗研究取得重大进展
• PLoS ONE：特定润滑剂的使用并不会增加艾滋病感染风险
• 美国不洁牙医致7000人或感染艾滋病病毒
• Am J Epidemiol：中国男男性行为是艾滋病传播的重要途径
• J Vir：我国艾滋病疫苗能有效控制HIV病毒通过粘膜途径感染 更多信息请点击：有关艾滋病更多资讯

Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 Envelope with potential use in microbicides.

Bovine colostrum (first milk) contains very high concentrations of IgG and on average 1 kg (500 g/L) of IgG can be harvested from each immunized cow immediately after calving. We used a modified vaccination strategy together with established production systems from the dairy-food industry for the large-scale manufacture of broadly neutralizing HIV-1 IgG. This approach provides a low-cost mucosal HIV preventive agent potentially suitable for a topical microbicide. Four cows were vaccinated pre- and/or post-conception with recombinant HIV-1 gp140 envelope (Env) oligomers of clade B or A, B and C. Colostrum and purified-colostrum IgG were assessed for cross-clade binding and neutralization against a panel of 27 Env-pseudotyped reporter viruses. Vaccination elicited high anti-gp140 IgG titers in serum and colostrum with reciprocal endpoint titers of up to 1x105. While non-immune colostrum showed some intrinsic neutralizing activity, colostrum from 2 cows receiving a longer duration vaccination regimen demonstrated broad HIV-1 neutralizing activity. Colostrum-purified polyclonal IgG retained gp140-reactivity and neutralization activity and blocked the binding of the b12 monoclonal antibody to gp140, showing specificity for the CD4 binding site. Colostrum derived anti-HIV antibodies offer a cost-effective option for preparing the substantial quantities of broadly neutralizing antibodies that would be needed in a low-cost topical combination HIV-1 microbicide.